The changing face of GIST: Implications for pathologists

Pathology

Volumn 46, Issue 2, 2014, Pages 141-148

  Hemmings, Chris ^a,b   Yip, Desmond ^c,d  

^a ST JOHN OF GOD HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CANBERRA HOSPITAL   (Australia)

^d Canberra Hospital   (Australia)

Author keywords

Gastrointestinal stromal tumour; Histopathology; Immunohistochemistry; KIT; Mutational analysis; PDGFRA; Risk stratification; SDHB

Indexed keywords

ARTICLE; CANCER STAGING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUTATION; PATHOLOGY; RISK ASSESSMENT;

GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM STAGING; RISK ASSESSMENT;

EID: 84896777737     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000047     Document Type: Article

References (66)

1. Miettinen M, Corless C, Lasota J., et al Gastrointestinal stromal tumours. In: Fletcher C, Bridge J, Hogendoorn C, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press, 2013.
2. Agaimy A, Wunsch P, Hofstaedter F., et al Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31: 113-20.
3. Kawanowa K, Sakuma Y, Sakurai S., et al High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37: 1527-35.
4. Fletcher C, Berman J, Corless C., et al Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.
6. Gold J, Gonen M, Gutierrez A., et al Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-52.
7. Rossi S, Miceli R, Messerini L., et al Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35: 1646-56.
8. Stratakis C, Carney J. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009; 266: 43-52.
9. Pasini B, McWhinney S, Bei T., et al Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008; 16: 79-88.
10. Lv A, Li Z, Tian X., et al SKP2 high expression, KIT exon 11 deletions,;1; and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS ONE 2013; 8: e62951.
11. Joensuu H, Vehtari J, Nishida T., et al Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-74.
12. Miettinen M, Sobin L, Lasota J. Gastrointestinal stromal tumors presenting as omental masses - A clinicopathologic analysis of 95 cases. Am J Surg Pathol 2009; 33: 1267-75.
13. Long K, Butrynski J, Blank S., et al Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation. Am J Surg Pathol 2010; 34: 907-12.
14. Irving J, Lerwill M, Young R. Gastrointestinal stromal tumors metastatic to the ovary: A report of five cases. Am J Surg Pathol 2005; 29: 920-6.
15. Hughes B, Yip D, Goldstein D., et al Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer 2004; 4: 74.
16. Jati A, Tatli S, Morgan J., et al Imaging features of bone metastases in patients with gastrointestinal stromal tumors. Diagn Interv Radiol 2012; 18: 391-6.
17. Nilsson B, Bumming P, Meis-Kindblom J, et al Gastrointestinal stromal tumors: the incidence, the prevalence, clinical course and prognostication in the preimatinib mesylate era: A population-based study in western Sweden. Cancer 2005; 103: 821-9.
18. Carney J, Sheps S, Go V., Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977; 296: 1517-8.
19. Carney J, Stratakis C. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from Carney triad. Am J Med Genet 2002; 108: 132-9.
20. McWhinney S, Pasini B, Stratakis C. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 2007; 357: 1054-6.
21. Miettinen M, Killian J, Wang Z., et al Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol 2013; 37: 234-40.
22. Dwight T, Benn D, Clarkson A., et al Loss of SDHA expression identifies SHDA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol 2013; 37: 226-33.
23. Postow M, Robson M. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clin Sarcoma Res 2012; 2: 16.
24. Matyakhina L, Bei T, McWhinney S., et al Genetics of Carney triad: Recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 2007; 92: 2938-43.
25. Miettinen M, Wang Z, Sarlomo-Rikala M, et al Succinate dehydrogenase-deficient GISTs: A clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011; 35: 1712-21.
26. Wagner A, Remillard S, Zhang Y., et al Loss of expression of SDHA predicts SHDA mutations in gastrointestinal stromal tumors. Mod Pathol 2013; 26: 289-94.
27. Gaal J, Stratakis C, Carney J., et al SDHB immunohistochemistry: A useful took in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 2011; 24: 147-51.
28. Chompret A, Kannengiesser C, Barrois M., et al PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004; 126: 318-21.
29. Neuhann T, Mansmann V, Merkelbach-Bruse S, et al A novel germline mutation (p. L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis. Am J Surg Pathol 2013; 37: 898-905.
30. Carballo M, Roig I, Aguilar F., et al Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 2005; 132: 361-4.
31. Maeyama H, Hidaka E, Ota H., et al Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120: 210-5.
32. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78.
33. Mussi C, Schildhaus H, Gronchi A., et al Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type I. Clin Cancer Res 2008; 14: 4550-5.
34. Wang J, Lasota J, Miettinen M. Succinate dehydrogenase subunit B (SDHB) is expressed in neurofibromatosis 1-associated gastrointestinal stromal tumors (GISTs): Implications for the SDHB expression based classification of GISTs. J Cancer 2011; 16: 90-3.
35. Maertens O, Prenen H, Debiec-Rychter M, et al Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006; 15: 1015-23.
36. Ponti G, Luppi G, Martorana D., et al Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Reports 2012; 23: 437-44.
37. Miettinen M, Kraszewska E, Sobin L., Lasota J. A nonrandom association between gastrointestinal stromal tumors and myeloid leukaemia. Cancer 2008; 112: 645-9.
38. Hanson J, Trent J, Yang D., Cooper K. Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): Mutation analysis and clinical implications of a rare morphological variant. Int J Surg Pathol 2011; 19: 653-7.
39. Antonescu C, Romeo S, Zhang L., et al Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am J Surg Pathol 2013; 37: 385-92.
40. Pauwels P, Debiec-Rychter M, Stul M., et al Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: A potential diagnostic pitfall. Histopathology 2005; 47: 41-7.
41. Koh Y, Lee H, Ohn D., et al The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. Jpn J Clin Oncol 2012; 42: 1020-7.
42. Mearadji A, den Bakker M, van Geel A, et al Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: A clinicopathological analysis. Anticancer Drugs 2008; 19: 607-12.
43. Rutkowski P, Nowecki Z, Nyckowski P., et al Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304-11.
44. Liegl B, Hornick J, Antonescu C., et al Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: A novel form of tumor progression. Am J Surg Pathol 2009; 33: 218-26.
45. Agaram N, Besmer P, Wong G., et al Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 2007; 13: 170-81.
46. West R, Corless C, Chen X., et al The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165: 107-13.
47. Liegl B, Hornick J, Corless C., Fletcher C. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33: 437-46.
48. Parfitt J, Rodriguez-Justo M, Feakings R., Novelli M. Gastrointestinal Kaposi's sarcoma: CD117 expression and the potential for misdiagnosis as gastrointestinal stromal tumour. Histopathology 2008; 52: 816-23.
49. Malik L, Hemmings C, Beshay V., et al Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missence (sic) mutations. Pathology 2013; 45: 604-6.
50. Casali P, Fumagalli E, Gronchi A. Adjuvant therapy of gastrointestinal stormal tumors (GIST). Curr Treat Options Oncol 2013; 13: 277-84.
51. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247-53.
52. Maier J, Lange T, Kerle I., et al Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harbouring activating mutations of CKIT or PDGFRA. Clin Cancer Res 2013; 19: 4854-67.
53. Braconi C, Bracci R, Bearzi I., et al Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008; 19: 1293-8.
54. Rink L, Godwin A. Clinical and molecular characteristics of gastrointestinal stromal tumor in the pediatric and young adult population. Curr Oncol Rep 2009; 11: 314-21.
55. Chou A, Chen J, Clarkson A., et al Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. Mod Pathol 2012; 25: 1307-13.
56. Lasota J, Wang Z, Kim S., et al Expression of the receptor for type I insulinlike growth factor (IGF1R) in gastrointestinal stromal tumors: An immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol 2013; 37: 114-9.
57. Tarn C, Rink L, Merkel E., et al Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008; 105: 8387-92.
58. Agaram N, Wong G, Guo T., et al Novel V600E BRAF mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours. Genes Chromosomes Cancer 2008; 47: 853-9.
59. Edge S, Byrd D, Compton C., et al Cancer Staging Handbook. 7th ed. New York: Springer, 2010. Chapter 16, Gastrointestinal stromal tumor.
60. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9.
61. Takahashi T, Nakajima K, Nishitani A., et al An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 2007; 12: 369-74.
62. Rutkowski P, Bylina E, Wozniak A., et al Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - The impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37: 890-6.
63. Sabah M, Cummins R, Leader M., Kay E. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: Markers with potential prognostic implications. Hum Pathol 2006; 37: 648-55.
64. Steinert D, Oyarzo M, Wang X., et al Expresion of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006; 106: 1617-23.
65. Montgomery E, Abraham S, Fisher C., et al CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 2004; 28: 168-77.
66. Wong N, Young R, Malcomson R., et al Prognostic indicators for gastrointestinal stromal tumours: A clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathol 2003; 43: 118-26.